Support The Moscow Times!

U.S. Biotech Firm Wins $5M Funding From Russian Government

A U.S. biotech firm has announced that a subsidiary has won a $4.6 million dollar contract in research funding from the Russian Industry and Trade Ministry, barely a week after announcing an earlier funding agreement with Moscow, a medical news website reported.

"Our goal is to advance two of our product candidates into the clinic in the coming year," Michael Fonstein, CEO and president of Cleveland BioLabs subsidiary Panacela said in a statement. "We are honored to partner with the ministry to support a substantial part of our clinical development program."

Under the three-year contract, the Russian ministry has agreed to match Panacela's funding for clinical and preclinical studies of its cancer vaccine Mobilan, reported Wednesday.

Ties between Panacela and the Russian government date back to when the firm was founded in 2011 as a joint venture between majority owner Cleveland BioLabs and Russia's state-run investment firm Rusnano, the website said.

On Oct. 16, Cleveland BioLabs announced that it had been awarded $4.6 million by the Russian Industry and Trade Ministry to fund studies into Entolimod, another potential cancer treatment.

… we have a small favor to ask.

As you may have heard, The Moscow Times, an independent news source for over 30 years, has been unjustly branded as a "foreign agent" by the Russian government. This blatant attempt to silence our voice is a direct assault on the integrity of journalism and the values we hold dear.

We, the journalists of The Moscow Times, refuse to be silenced. Our commitment to providing accurate and unbiased reporting on Russia remains unshaken. But we need your help to continue our critical mission.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just 2. It's quick to set up, and you can be confident that you're making a significant impact every month by supporting open, independent journalism. Thank you.


Read more